Refractory Generalised Myasthenia Gravis (gMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Myasthenia gravis (MG) is a clinically heterogeneous autoimmune disorder affecting the neuromuscular junction. It is characterized by fatigable weakness of voluntary muscles. The onset of MG can occur at any age, but in the adult-onset form, there is a bimodal peak. Generalized MG, which commonly affects women under the age of 40, has a higher prevalence than in men. Men, on the other hand, are more likely to develop MG after the age of 60. The underlying cause of MG is autoimmune in nature. Self-reactive antibodies target acetylcholine receptors, which are crucial for facilitating muscle contraction and movement. However, approximately 15% of individuals with generalized MG do not have antibodies against acetylcholine receptors. Instead, these patients possess self-reactive antibodies against other important molecules involved in nerve-muscle communication, such as muscle-specific kinase (MuSK). Nearly all patients who develop generalized MG do so within two or three years after the initial display of symptoms. The exact pathogenesis of MG remains unknown. However, it is associated with circulating antibodies against various muscle receptors, including acetylcholine receptor (AChR) and muscle-specific receptor tyrosine kinase (MuSK). Another targeted molecule, the low-density lipoprotein receptor-related protein 4 (LRP4), has also been identified. The thymus is believed to trigger the production of antibodies against AChR in certain forms of the disease. These antibodies are known to have a pathogenic role in all forms of MG. Drug-induced MG can occur due to the use of medications such as D-penicillamine, interferon alpha, or as a result of bone marrow transplantation. In some cases, an initial infection (EBV) may be responsible for the development of MG. Muscle weakness is the primary manifestation of MG. Approximately 85% of patients experience generalized myasthenia gravis, which affects the proximal muscles of the extremities and trunk. Generalized MG (gMG) treatments include thymectomy, immunosuppressive therapies, intravenous immunoglobulins, and plasmapheresis.
• The estimated prevalence of MG in the United States is 14 to 20 cases per 100,000 individuals.

Thelansis’s “Refractory Generalised Myasthenia Gravis (gMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Generalised Myasthenia Gravis (gMG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Refractory Generalised Myasthenia Gravis (gMG) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Refractory Generalised Myasthenia Gravis (gMG) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Refractory Generalised Myasthenia Gravis (gMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033